Baidu
map

Neurology:阿司匹林抵抗与卒中严重程度和梗死体积增加相关

2016-04-23 MedSci MedSci原创

为了研究是否阿司匹林抵抗与首次卒中的严重程度和梗死体积增加相关,对在服用阿司匹林期间发生急性卒中的患者进行弥散加权成像(DWI)检查。

为了研究是否阿司匹林抵抗与首次卒中的严重程度和梗死体积增加相关,对在服用阿司匹林期间发生急性卒中的患者进行弥散加权成像(DWI)检查。

我们研究了总共310个患者,确定为急性卒中发作48小时之内。所有的患者都在发病前服用阿司匹林至少7天。阿司匹林抵抗, 是指阿司匹林治疗中产生的高残留血小板反应性(HRPR),使用 VerifyNow 检验,以及阿司匹林反应单位≥550。首次卒中严重程度通过NIH卒中评分量表及进行评分。使用DWI估计梗死面积。

86个患者(27.7%)发生了HRPR。 HRPR组首次NIHSS评分(中位数[四分位间距])比非HRPR组高(6 [3-15] vs 3 [1-8], p < 0.001)。DWI梗死体积也是HRPR组较非HRPR组大(5.4 [0.8-43.2] vs 1.7 [0.4-10.3], p = 0.002)。多元回归分析显示HRPR组NIHSS评分高2.1分(95%CI 0.8-4.0, p < 0.001),DWI体积增加了2.3 cm(3) (95%CI 0.4-3.9, p < 0.001)。

结论:阿司匹林抵抗与卒中发作前使用阿司匹林的患者发生卒中的严重程度和梗死体积增加相关。

原始出处:


Oh MS1, Yu KH2, Lee JH2, Jung S2, et al,Aspirin resistance is associated with increased stroke severity and infarct volume.Neurology. 2016 Apr 8.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999681, encodeId=f58e1999681b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 09 03:01:00 CST 2017, time=2017-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82789, encodeId=d4fc82e8924, content=非常重要的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Tue Apr 26 09:44:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82628, encodeId=a7a18262871, content=怎么去发哪?, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61ad1712805, createdName=C3, createdTime=Sun Apr 24 23:10:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81889, encodeId=15a38188925, content=阿司匹林抵抗与卒中发作前使用阿司匹林的患者发生卒中的严重程度和梗死体积增加相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Apr 24 05:47:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81874, encodeId=efb2818e4b9, content=可惜这边检查不足, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sat Apr 23 23:14:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81862, encodeId=ce6a81862f6, content=药物抵抗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Sat Apr 23 21:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=)]
    2017-04-09 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999681, encodeId=f58e1999681b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 09 03:01:00 CST 2017, time=2017-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82789, encodeId=d4fc82e8924, content=非常重要的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Tue Apr 26 09:44:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82628, encodeId=a7a18262871, content=怎么去发哪?, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61ad1712805, createdName=C3, createdTime=Sun Apr 24 23:10:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81889, encodeId=15a38188925, content=阿司匹林抵抗与卒中发作前使用阿司匹林的患者发生卒中的严重程度和梗死体积增加相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Apr 24 05:47:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81874, encodeId=efb2818e4b9, content=可惜这边检查不足, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sat Apr 23 23:14:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81862, encodeId=ce6a81862f6, content=药物抵抗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Sat Apr 23 21:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=)]
    2016-04-26 jjzouyan

    非常重要的文献

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1999681, encodeId=f58e1999681b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 09 03:01:00 CST 2017, time=2017-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82789, encodeId=d4fc82e8924, content=非常重要的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Tue Apr 26 09:44:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82628, encodeId=a7a18262871, content=怎么去发哪?, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61ad1712805, createdName=C3, createdTime=Sun Apr 24 23:10:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81889, encodeId=15a38188925, content=阿司匹林抵抗与卒中发作前使用阿司匹林的患者发生卒中的严重程度和梗死体积增加相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Apr 24 05:47:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81874, encodeId=efb2818e4b9, content=可惜这边检查不足, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sat Apr 23 23:14:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81862, encodeId=ce6a81862f6, content=药物抵抗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Sat Apr 23 21:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=)]
    2016-04-24 C3

    怎么去发哪?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1999681, encodeId=f58e1999681b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 09 03:01:00 CST 2017, time=2017-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82789, encodeId=d4fc82e8924, content=非常重要的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Tue Apr 26 09:44:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82628, encodeId=a7a18262871, content=怎么去发哪?, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61ad1712805, createdName=C3, createdTime=Sun Apr 24 23:10:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81889, encodeId=15a38188925, content=阿司匹林抵抗与卒中发作前使用阿司匹林的患者发生卒中的严重程度和梗死体积增加相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Apr 24 05:47:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81874, encodeId=efb2818e4b9, content=可惜这边检查不足, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sat Apr 23 23:14:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81862, encodeId=ce6a81862f6, content=药物抵抗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Sat Apr 23 21:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=)]
    2016-04-24 壹生

    阿司匹林抵抗与卒中发作前使用阿司匹林的患者发生卒中的严重程度和梗死体积增加相关。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1999681, encodeId=f58e1999681b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 09 03:01:00 CST 2017, time=2017-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82789, encodeId=d4fc82e8924, content=非常重要的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Tue Apr 26 09:44:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82628, encodeId=a7a18262871, content=怎么去发哪?, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61ad1712805, createdName=C3, createdTime=Sun Apr 24 23:10:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81889, encodeId=15a38188925, content=阿司匹林抵抗与卒中发作前使用阿司匹林的患者发生卒中的严重程度和梗死体积增加相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Apr 24 05:47:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81874, encodeId=efb2818e4b9, content=可惜这边检查不足, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sat Apr 23 23:14:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81862, encodeId=ce6a81862f6, content=药物抵抗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Sat Apr 23 21:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=)]
    2016-04-23 明崖

    可惜这边检查不足

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1999681, encodeId=f58e1999681b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 09 03:01:00 CST 2017, time=2017-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82789, encodeId=d4fc82e8924, content=非常重要的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Tue Apr 26 09:44:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82628, encodeId=a7a18262871, content=怎么去发哪?, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61ad1712805, createdName=C3, createdTime=Sun Apr 24 23:10:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81889, encodeId=15a38188925, content=阿司匹林抵抗与卒中发作前使用阿司匹林的患者发生卒中的严重程度和梗死体积增加相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Apr 24 05:47:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81874, encodeId=efb2818e4b9, content=可惜这边检查不足, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sat Apr 23 23:14:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81862, encodeId=ce6a81862f6, content=药物抵抗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Sat Apr 23 21:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=)]
    2016-04-23 Lisa971

    药物抵抗。

    0

相关资讯

老年心血管病患者阿司匹林抵抗率高

 解放军总医院曹剑、范利、刘霖等在2011年第9期《中华老年心脑血管病杂志》发表一项研究,评价了老年心血管病患者阿司匹林抵抗的发生率及可能的潜在危险因素。结果提示,老年心血管病患者阿司匹林抵抗发生率较高,空腹血糖、P选择素为阿司匹林抵抗的危险因素,硝酸酯药物为其保护性因素。   研究者选择老年心血管病患者454例,分为阿司匹林抵抗组111例,阿司匹林敏感组343例。口服阿司匹林(≥75 mg)

Baidu
map
Baidu
map
Baidu
map